1. Introduction {#sec1}
===============

Ionic liquids (also frequently referred to as ionic solvents) are salts - normally composed of organic cations and inorganic anions - with a melting temperature below 100 °C and often, they are liquids at ambient temperatures ([@bib59]). Given their relative low volatility, they have been proposed as environmentally-friendly solvents ([@bib59]).

The modern era of ionic liquid development started with the generation of 1-butylpyridinium chloride--aluminium chloride mixtures in the 1970s ([@bib12]; [@bib59]; [@bib58]). However, they are man-made chemicals that do not exist naturally in biological systems and as a consequence, resist degradation in the environment.

Ionic liquids may currently find use in plant protection products e.g. herbicidal phenoxyacid derivatives. ([@bib43]). They may also be used in chemical syntheses, biotechnology and chemical engineering - in applications such as cellulose processing, as lubricants, corrosion inhibitors and battery electrolytes, for water purification, chemical separation and extraction and biofuel production ([@bib42]).

The ionic liquid 1-octyl-3-methylimidazolium (M8OI, also referred to as C8\[mim\]) was recently found at high levels in soils in close proximity to a landfill waste site in the North East of England, and to have the potential to trigger an auto-immune liver disease primary biliary cholangitis (PBC) ([@bib48]). M8OI is an 1-alkyl-3-methyl imidazolium ionic liquid, one of the four major chemical classes of ionic liquids that also includes N-alkyl-pyridinium, tetraalkyl-ammonium and tetraalkyl phosphonium liquids ([@bib32]). This article reviews the current state of knowledge regarding the toxic effects of M8OI in mammalian and environmental models and their potential to trigger PBC.

2. The toxicology database for M8OI {#sec2}
===================================

There are a limited number of studies examining the toxicity of M8OI. Given that toxicity of the cation may be influenced by its anion, the salt used in the studies is identified.

2.2. Signalling pathway interactions {#sec2.1}
------------------------------------

A number of bioassays have been performed on M8OI (Cl-salt) and are freely available (<https://pubchem.ncbi.nlm.nih.gov/compound/2734223>), populated from the Toxicology in the 21st Century (Tox21) program. These data indicate that M8OI interacts with the human sonic hedgehog signaling (Shh); androgen receptor; estrogen receptor alpha; estrogen related receptor; pregnane X receptor and retinoid-related orphan receptor gamma signalling pathways. M8OI is also reported to be a disruptor of mitochondrial membrane potential and to be cytotoxic.

2.3. In vitro (mammalian) studies {#sec2.2}
---------------------------------

M8OI (as the Cl^−^ salt) was shown to increase oxidative stress and induce the apoptosis of a human hepatocarcinoma cell line (QGY-7701) by [@bib16], with an EC~50~ of approximately 360 μM M8IO (as the Br^−^ salt) was also reported to be cytotoxic to the human hepatoma HepG2 cell line but, in agreement with our observations (unpublished), high concentrations - EC~50~ of 439.46 μM after 24 h exposure -- were required ([@bib24]). An examination of a variety of toxic endpoints suggested that an induction of reactive oxygen species was an early effect of exposure and that the mode of cell death was apoptotic based on induction of caspase activities ([@bib24]).

[@bib27] showed that imidazolium-based ionic liquids (as the Cl^−^ salts) intercalate with DNA isolated from calf thymus, with ionic chain length giving rise to increasing binding strength. Thus, M8OI was shown to be relatively weak at quenching the fluorescence of an ethidium bromide-DNA complex at 666 μM (\<10%) whereas a related ionic liquid in which the octyl chain was replaced with a 16 carbon chain at this concentration resulted in \>80% fluorescence quenching.

[@bib29] further investigated the effects of M8OI (as the Br^−^ salt) in HepG2 cells and demonstrated that exposure resulted in changes in heat shock protein 70 and heat shock protein 90 expression and generally inhibited the total anti-oxidative capacity of the cells. There was increased phosphorylation of p53, mitochondrial membrane disruption, cyclooxygenase-2 activation, Bcl-2 family protein modulation, cytochrome *c* and Smac/DIABLO release and inhibition of apoptosis inhibitory protein-2 (c-IAP2) and survivin. The mitochondrial effects and toxicity were partly inhibited by N-acetyl-cysteine.

The liver progenitor B-13 cell line ([@bib47]) was observed to be markedly sensitive to the Cl^−^ salt of M8OI (EC~50~ for MTT reduction \~ 50 μM) and at least 10-fold more sensitive than the hepatocyte-like (B-13/H) cells derived from them ([@bib48]). The earliest effect (within minutes) observed after exposure to M8OI was an inhibition of oxygen consumption in both B-13 and B-13/H cells. This resulted in AMPK phosphorylation and enhanced glucose consumption. Replacing glucose with galactose also sensitized cells to M8OI. Around the time of glucose depletion, the cells underwent apoptosis as evidenced by an induction of caspase 3/7 activity and nucleosomal DNA cleavage.

These data suggest that an interaction of M8OI with mitochondria is likely a key initiating event in the adverse outcome pathway for M8OI toxicity.

2.4. Published in vivo (Mammalian) studies {#sec2.3}
------------------------------------------

Only one study has been published, to our knowledge, in a mammalian species in vivo. The acute toxic effects of 1-methyl-3-octylimidazolium bromide \[M8IO^+^ Br^−^\] in mice has been examined. The study was limited to potential adverse effects up to 24 h after an i.p. administration. Ten hours after administration, the authors report histopathological changes in the liver and calculated an LD~50~ of 35.7 mg/kg bw ([@bib62]).

In our hands, the target organ for the toxic effects of M8OI (as the Cl-salt) after i. p. injection was seen to be the kidney based on increases in serum creatinine, urinary protein, urinary kidney injury molecule 1 (Kim1) and histopathological alterations. These effects were clearly evident at doses of 10 mg/kg bw per day (dosed twice over a 24 h period). Effects on the liver at this dose were restricted to depletions of glycogen and portal tract changes in the absence of any overt histopathological changes associated with tissue injury ([@bib22], manuscript in submission). Given that the proposed mechanism by which M8OI interacts with cells is via an inhibition of oxidative phosphorylation in mitochondria, the kidney may be sensitive to M8OI through its reliance on cellular respiration for reabsorption. Although constituting around 0.5% of body mass, kidneys consume 10% of the oxygen used in cellular respiration ([@bib3]). The kidney may also likely be the primary route for elimination of systemic M8OI and therefore be exposed to high intracellular concentrations of M8OI.

2.5. Published studies with model indicators of environmental impact {#sec2.4}
--------------------------------------------------------------------

M8OI \[as the Br^−^ salt\] has been shown to be acutely toxic to frogs (*R. nigromaculata*) during early embryonic development, with the median lethal concentration values at the early cleavage, early gastrula and neural plate stages of development being 85.1, 43.4, and 42.4 mg/L respectively after 96 h exposure (equivalent to 309, 158 and 154 μM respectively) ([@bib23]).

M8OI (as the Cl^−^ salt) reduced MTT reduction activity and replication in *E. coli* (DH5a) suspension cultures that was associated with increased cell membrane permeability, with significant effects seen at the lowest concentration examined of 100 μM ([@bib17]).

M8OI (as the hexafluorophosphate salt) was shown to irreversibly inhibit the germination of wheat seedlings at 4 mg/L (equivalent to 11.8 μM) after 7 days of exposure ([@bib25]). M8OI as either the Cl^−^ or Br^−^ salts were also toxic, the anion reported by the authors to have no impact on toxicity ([@bib28]).

Effects on the growth of green algae (S. obliquus) was examined by [@bib26] who demonstrated that M8IO and other structurally-related ionic liquids (as the Cl^−^ salts) affected membrane permeability, cell morphology and growth (IC~50~ was determined to be between 0.69 and 0.86 mg/L, equivalent to 3.0--3.7 μM).

[@bib8] examined the effect of M8OI (as the Br^−^ salt) on the marine diatom (phytoplankton) S. costatum and demonstrated that photosynthesis and cell growth were inhibited, the latter with an EC~50~ of 17.9 and 39.9 mg/L (equivalent to 65 and 145 μM) after 48 and 96 h exposure respectively.

[@bib63] indicated that M8OI (as the Br^−^ salt) was genotoxic to planarians (flatworms, using D. japonica) through use of a randomly amplified polymorphic DNA assay. Using this assay, the authors report evidence of a dose-responsive genotoxicity (4, 7 and 9 changes detected) after 1 day exposure at concentrations of 74, 147 and 220 mg/L respectively (equivalent to 270, 530 and 800 μM).

[@bib38] exposed fish (*P. dabryanus*) to M8OI (as the Cl^−^ salt). After 48 h there was 20% mortality when fish were exposed to 126 mg/L and 100% mortality when exposed to 360 mg/L (equivalent to 550 μM and 1.6 mM respectively). The authors reported that the liver was a target organ with evidence for oxidative stress DNA damage and apoptosis presented.

Three types of M8OI (either as the Cl^−^, Br^−^ or tetrafluoroborate) were examined for their effects on wheat seedlings (up to 800 mg/kg in brown soil) over a 13 day period ([@bib60]). All three ionic liquids inhibited growth (shoot length, root length, pigment content and proline content) of wheat seedlings which was associated with the generation of reactive oxygen species.

M8OI (as the nitrate) significantly reduced the microbial populations (bacteria, fungi and actinomycetes) and diversity at 10.0 mg/kg in brown soil on days 10, 20, 30, and 40 ([@bib64]).

Silver carp (*Hypophthalmichthys molitrix*) were exposed for 60 days to M8OI (as the Br^−^) at concentrations of 1.09 or 4.38 mg/L ([@bib30]). According to the authors, an elevation in a variety of serum markers and biochemical assays indicated fish organ damage and alterations in brain, gill, intestine, kidney, liver and muscle enzymes suggestive of oxidative stress. Some changes in xenobiotic metabolising enzymes activities (erythromycin-N-demethylase and glutathione S-transferases); increases in inflammatory markers (iNOS, IL-1β, TNF-α and NF-κB), altered levels of TGF-β and apoptosis markers were reported in liver. An additional report focussed on effects in the spleen ([@bib31]).

The effect of M8OI (as either the nitrate or Cl^−^) on marine diatom Phaeodactylum tricornutum growth was examined and was shown to be inhibitory, with 96-h EC~50~ values of 24.0 and 33.6 mg/L respectively ([@bib6]). Photosynthesis was considered by the authors to have been inhibited based on significant decreases of chlorophyll *a* and damage to PSII reaction centres. Content of soluble protein superoxide dismutase and catalase initially increased significantly, likely as an adaptive response prior to decreases in the cultures with higher concentrations of ILs (≥20 mg/L).

The current database on the toxic effects of M8OI in mammalian systems is therefore extremely limited. There is currently only a single limited report published on the effects of acute M8OI exposure in mice. In contrast, the number of studies on the effects of M8OI in model indicators of environmental impact are more extensive. These data overall suggest that if levels accumulate above a variable threshold, adverse effects may be seen in the environment, experimental animals and man.

3. Exposure to M8OI {#sec3}
===================

Although M8OI and structurally-related methylimidazolium ionic liquids have toxic effects in cells in vitro, in mice and in a variety of model indicators of environmental impact, there is currently no data to determine whether there is significant contamination of the environment and/or exposure in man to these chemicals.

Interrogation of the UK National Poisons Information Service\'s (<http://www.npis.org/toxbase.html>) TOXBASE, which provides information on pharmaceuticals, chemicals (agricultural, household and industrial), plants and animals, suggests that M8OI is not a listed ingredient (Prof Allister Vale, National Poisons Information Service UK, personal communication). M8OI is also not listed as an ingredient in any pesticide in the UK according to the UK Health and Safety Executive COPR Database (<https://webcommunities.hse.gov.uk/connect.ti/pesticides/>); in any cosmetic in the EU (<https://ec.europa.eu/growth/sectors/cosmetics/cosing_en>) or in any household product in US (<https://hpd.nlm.nih.gov/cgi-bin/household/list?tbl=TblChemicals&alpha=A>). However, over 60 methylimidazolium ionic liquids have been registered with the European Chemicals Agency (ECHA), several with toxicity dossiers, suggesting they are being used in the EU such that they do not require to be listed as an ingredient in any product.

3.1. ECHA database {#sec3.1}
------------------

The ECHA implements the EU\'s chemicals legislation and is an extensive source of information on the chemicals manufactured and imported in Europe. In the EU, there is an obligation under the Classification, Labelling and Packaging (CLP) Regulation ((EC) No 1272/2008) that requires manufacturers and importers to submit classification and labelling information for the substances they are placing on the market. This information is publicly available within the C&L Inventory held by ECHA (<https://echa.europa.eu/regulations/clp/cl-inventory>). Examination of this database indicates that there are currently 5 different M8OI salts pre-registered with ECHA, but since no data on their toxicity have been submitted, their production level by any single producer should be less than 100 tonnes/annum (Dr D Bell, ECHA - personal communication). Interrogating the database for structurally-related methylimidazolium ionic liquids currently shows that 31 ethyl, 22 butyl, 4 hexyl and 2 decyl substituted 3-methylimidazolium ionic salts -- in addition to the 5 octyl/M8OI liquids -- are listed (see [Table 1](#tbl1){ref-type="table"}). [Table 1](#tbl1){ref-type="table"} indicates that a number of shorter chain variants are registered which suggests that these variants are being used industrially. However, in several cases, their production levels are confidential so that there remains uncertainty as to whether there is significant hazard from these chemicals at the current time.Table 11-alkyl-3-methylimidazolium (2C--10C alkyl) ionic liquids registered with ECHA.Table 1\#ChemicalCAS \#EC list \#CLPProduction LevelsNotified classification and labelling according to CLP criteria - Human Health hazards[a](#tbl1fna){ref-type="table-fn"}2C (Ethyl)11-Ethyl-3-methylimidazolium iodide35935-34-3609-195-2Data lacking for all toxicity studies21-Ethyl-3-methylimidazolium methyl carbonate251102-25-7607-553-2Data lacking for all toxicity studies31-Ethyl-3-methylimidazolium ethyl Sulfate342573-75-5608-962-9Data lacking for all toxicity studies41-Ethyl-3-methylimidazolium bis(trifluoromethanesulfonyl)imide174899-82-2700-235-5Acutely toxic orally and dermally but no data available51-Ethyl-3-methylimidazolium nitrate143314-14-1626-456-6Data lacking for all toxicity studies61-Ethyl-3-methylimidazolium dibutyl phosphate869858-84-4628-587-4Data lacking for all toxicity studies71-Ethyl-3-methylimidazolium thiocyanate331717-63-6628-857-1Acutely toxic orally, dermally and by inhalation but no data available81-Ethyl-3-methylimidazolium L-(+)-lactate878132-19-5629-129-6Data lacking for all toxicity studies91-Ethyl-3-methylimidazolium methyl sulfate516474-01-4629-280-8Data lacking for all toxicity studies101-Ethyl-3-methylimidazolium tetrachloroaluminate80432-05-9629-638-3Data lacking for all toxicity studies111-Ethyl-3-methylimidazolium 1,1,2,2-tetrafluoroethanesulfonate880084-63-9663-145-4Data lacking for all toxicity studies121-Ethyl-3-Methylimidazolium hydrogen carbonate947601-94-7666-647-1Data lacking for all toxicity studies131-Ethyl-3-methylimidazolium hexafluorophosphate \[for Molten Salt\]155371-19-0671-175-4Data lacking for all toxicity studies141-Ethyl-3-methylimidazolium hydrogen sulfate412009-61-1679-296-4Data lacking or inconclusive151-Ethyl-3-methylimidazolium p-toluenesulfonate328090-25-1680-026-2Specific target organ -- lungs, but no data available161-Ethyl-3-methylimidazolium 2-(2-methoxyethoxy)ethyl sulfate790663-77-3680-032-5Data lacking or inconclusive171-Ethyl-3-methylimidazolium tetrachloroferrate850331-04-3680-125-0Data lacking or inconclusive181-Ethyl-3-methylimidazolium trifluoro(trifluoromethyl)borate681856-28-0680-165-9Data lacking or inconclusive191-Ethyl-3-methylimidazolium aminoacetate766537-74-0684-727-4Acutely toxic orally but no data available201-Ethyl-3-methylimidazolium (S)-2-aminopropionate766537-81-9684-730-0Acutely toxic orally but no data available211-Ethyl-3-methylimidazolium diethyl phosphate848641-69-0684-879-1Acutely toxic orally but no data available221-Ethyl-3-methylimidazolium dimethylphosphate945611-27-8689-585-7Acutely toxic orally but no data available231-Ethyl-3-methylimidazolium benzoate150999-33-0695-723-7Registration dossier available <https://echa.europa.eu/registration-dossier/-/registered-dossier/23760>0--10 tonnes per annum \[1\]241-Ethyl-3-methylimidazolium chloride/aluminiumchloride (1:1.5)939-824-9Data lacking for all toxicity studies251-Ethyl-3-methylimidazolium methylcarbonate939-827-5Acutely toxic orally, dermally and by inhalation but no data available Specific target organ -- CNS, but no data available261-ethyl-3-methylimidazolium bis(fluorosulfonyl)imide235789-75-0825-567-9Specific target organ -- Lung, but no data available273-ethyl-1-methyl-1H-Imidazolium chloride (1:1)65039-09-0613-739-4Acutely toxic orally. Data lacking or conclusive but not sufficient for classification Registration dossier available <https://echa.europa.eu/registration-dossier/-/registered-dossier/16488>Tonnage Data Confidential \[2\]283-ethyl-1-methyl-1H-Imidazolium salt with N-cyanocyanamide (1:1)370865-89-7609-330-5Data lacking or conclusive but not sufficient for classification\
Registration dossier available <https://echa.europa.eu/registration-dossier/-/registered-dossier/21257>10--100 tonnes per annum \[3\]293-Ethyl-1-methyl-1H-imidazolium 1,1,1-trifluoromethanesulfonate (1:1)145022-44-2680-002-1Data lacking or inconclusive\
Registration document available <https://echa.europa.eu/registration-dossier/-/registered-dossier/12728>0--10 tonnes per annum \[4\]301-ethyl-3-methyl-1H-imidazol-3-ium-acetate143314-17-4604-344-8Data lacking or inconclusive.\
Urgent need for toxicological assessment before it can be used in numerous technologies ([@bib41]).\
Registration document available <https://echa.europa.eu/registration-dossier/-/registered-dossier/25928/7/3/2>0--10 tonnes per annum\
<https://proionic.com/news/reach-registration-EMIM-OAc.php>311-ethyl-3-methyl-1H-imidazol-3-ium tetrafluoroborate143314-16-3671-177-5Data lacing or conclusive but not sufficient for classification.\
Registration document available <https://echa.europa.eu/registration-dossier/-/registered-dossier/6591>10--100 tonnes per annum4C (Butyl)11-Butyl-3-methylimidazolium methyl carbonate solution916850-37-8618-781-7Acutely toxic orally, dermally and by inhalation. Data often lacking or conclusive but not sufficient for classification. Toxic to all organs.21-Butyl-3-methylimidazolium bis(trifluoromethanesulfonyl)imide174899-83-3605-742-4Acutely toxic orally and dermally. Data lacking or incoclusive. Toxic to all organs. Toxic to CNS.31-Butyl-3-methylimidazolium bromide85100-77-2617-674-2Data lacking or inconclusive.41-Butyl-3-methylimidazolium methyl sulfate401788-98-5609-790-7Data lacking for all toxicity studies.51-Butyl-3-methylimidazolium iodide65039-05-6619-502-1Data lacking or inconclusive.61-Butyl-3-methylimidazolium dibutyl phosphate663199-28-8628-122-5Specific target organ toxicity -- not identified, no data available.71-Butyl-3-methylimidazolium dicyanamide448245-52-1628-456-1Acutely toxic orally. Specific target organ toxicity -- not identified, no data available.81-Butyl-3-methylimidazolium trifluoroacetate174899-94-6628-479-7Specific target organ toxicity -- not identified, no data available.91-Butyl-3-methylimidazolium nitrate179075-88-8629-008-8Specific target organ toxicity -- not identified, no data available.101-Butyl-3-methylimidazolium hydrogen carbonate366491-15-8629-216-9Specific target organ toxicity -- not identified, no data available.111-Butyl-3-methylimidazolium tetrafluoroborate174501-65-6638-831-1Acutely toxic orally. Specific target organ toxicity -- lungs, no data available.121-Butyl-3-methylimidazolium trifluoromethanesulfonate174899-66-2678-094-3Acutely toxic orally. Specific target organ toxicity --lungs, no data available. Data lacking or conclusive but not sufficient for classification.131-butyl-3-methylimidazolium tetrachloroferrate359845-21-9678-175-3Data lacking or inconclusive.141-Butyl-3-methylimidazolium methanesulfonate342789-81-5679-383-7Acutely toxic orally.151-Butyl-3-methylimidazolium trifluoro(trifluoromethyl)borate741677-68-9679-580-8Data lacking or inconclusive.161-Butyl-3-methylimidazolium thiocyanate344790-87-0682-764-0Acutely toxic orally, dermally and by inhalation but no data available. Specific target organ toxicity -- not identified, no data available.171-Butyl-3-methylimidazolium hydrogen sulfate262297-13-2684-205-6Data lacking for all toxicity studies.181-Butyl-3-methylimidazolium tetrachloroaluminate80432-09-3684-907-2Data lacking for all toxicity studies.191-Butyl-3-methylimidazolium tribromide820965-08-0691-470-1Data lacking or inclonclusive.201-Butyl-3-methylimidazolium chloride/aluminiumchloride (1:1.5)939-823-3Data lacking for all toxicity studies.211-Butyl-3-methylimidazolium methylcarbonate939-828-0Acutely toxic orally, dermally and by inhalation but no data available. Specific target organ toxicity -- CNS, no data available.223-butyl-1-methyl-1H-imidazol-3-ium chloride79917-90-1460-120-8Registration dossier available <https://echa.europa.eu/registration-dossier/-/registered-dossier/12929>\
This ionic liquid has also been reviewed by the [@bib40].Tonnage Data Confidential \[5\].6C (Hexyl)11-Hexyl-3-methylimidazolium trifluoromethanesulfonate460345-16-8628-457-7Specific target organ toxicity -- not identified, no data available21-Hexyl-3-methylimidazolium hexafluorophosphate304680-35-1629-544-2Specific target organ toxicity -- not identified, no data available31-Hexyl-3-methylimidazolium tetrafluoroborate244193-50-8680-100-4Acutely toxic orally but no data available, data lacking or inconclusive41-Hexyl-3-methylimidazolium chloride171058-17-6690-853-0Data lacking toxicity studies8C (Octyl) i.e. M8OI11-Methyl-3-n-octylimidazolium hexafluorophosphate304680-36-2627-887-2Specific target organ toxicity -- not identified, no data available21-Methyl-3-n-octylimidazolium trifluoromethanesulfonate403842-84-2627-928-4Specific target organ toxicity -- not identified, no data available31-Methyl-3-n-octylimidazolium chloride64697-40-1629-637-8Specific target organ toxicity -- not identified, no data available41-Methyl-3-n-octylimidazolium bromide61545-99-1677-551-4Data lacking or conclusive but not sufficient for classification\
Specific target organ -- Lung, but no data available51-Methyl-3-n-octylimidazolium tetrafluoroborate244193-52-0801-285-1Data lacking for all toxicity studies10C (Decyl)11-Decyl-3-methylimidazolium tetrafluoroborate244193-56-4627-902-2Specific target organ toxicity -- not identified, no data available21-Decyl-3-methylimidazolium chloride171058-18-7629-293-9Specific target organ toxicity -- not identified, no data available[^1]

3.2. Discovery of M8OI in the environment {#sec3.2}
-----------------------------------------

The Newcastle study was primarily set up to determine proof of concept whether extracts from soil samples may be screened for the presence of xenobiotics that interact with receptors known to respond to xenobiotics or are toxic to cells. To maximise the potential value of the pilot study, samples were taken from an area in the north east of England that was of potential interest with regard to PBC incidence. The area contained a landfill site and thirteen sites (from allotments, footpaths and the roadside verges) surrounding the peri-urban landfill site were sampled (see [Fig. 1](#fig1){ref-type="fig"}).Fig. 1**Approximate location of sampling sites around the landfill waste site used in**[@bib48]. Prevailing wind is westerly/south westerly.Fig. 1

In accordance with Article 6 of EU directive 199/31/EC on the landfill of waste, the site was (and remains) designated as a non-hazardous waste site. As a non-hazardous waste site, it should only be used for municipal waste, non-hazardous waste of any other origin which meets the criteria set out on Annex II of the directive and stabilized, non-reactive hazardous waste. The landfill site was originally an abandoned stone quarry that operated from the 1930s to the 1960s. It has been used as a landfill site since the late 1990s. The landfill sampling locations were also adjacent to a disused colliery and associated light railway (that operated between 1890 and 1960), remediated in 1990 and converted into public open space. Other land uses in the area have been semi-rural and residential throughout the history of the site. Three separate control sites were also sampled for comparison (from the University farm in rural Northumberland with a controlled fertiliser regime for the last 130 years and from two gardens from separate urban areas in the region). Thus, all sample sites (near landfill and control) were from a region that has experienced a long period of urban growth and industrialisation with particular emphasis on heavy industries such as steel, ship building and coal mining. These industries have dwindled in the last 30 years and the area around the landfill is currently classified as residential and green space (Generalised Land Use Database -- Office of National Statistics, 2005). However, the region has been left with a legacy of industrial contamination associated with these industries, specifically toxic elements and polyaromatic hydrocarbons (PAHs). The north east of England is not unusual in having this, and most of the urban areas of the UK share this legacy ([@bib18]).

Chemicals present in soil samples were extracted into aqueous, ethanol and chloroform liquids (for full methodological details, see [@bib48]). Mammalian cells in culture were initially exposed to these extracts (up to 1% v/v; chloroform extracts were dried and re-suspended in an equivalent volume of DMSO) to screen for toxic effects (e.g. primarily using the MTT screening assay) over several days. There was no apparent microbial contamination of the treated mammalian cell cultures leading to toxic effects (e.g. associated with microbial growth) over the timescale employed, despite the origin of the extracts ([@bib48]). Cells were then transfected with promoter-reporter gene constructs (up to 0.1% v/v, below levels that caused toxicity; chloroform extracts were dried and re-suspended in an equivalent volume of DMSO) as a screen for the potential presence of chemicals activating the aryl hydrocarbon receptor (AhR), pregnane X receptor (PXR), peroxisome proliferator activated receptor alpha (PPARα), estrogen receptor (ER) and androgen receptor (AR). This approach was designed to screen for chemicals capable of activating or inhibiting the receptors. In addition, established assays for environmental contaminants were performed. Elements (As, B, Ba, Cd, Co, Cr, Cu, Pb, Mn, Hg, Mo, Ni, Se and Zn) were determined in soil directly via *aqua regia* digestion by inductively coupled plasma optical emission spectrometry (ICP-OES). The chloroform extracts were analysed for PAHs by GC-MS analysis. Pesticide analysis was determined by UPLC® coupled with Xevo TQ-S (Waters). For full methodological details, see [@bib48].

The levels of 14 toxic heavy metals (e.g. lead, see [Fig. 2](#fig2){ref-type="fig"}a) were determined ([@bib48]). As can be seen for lead levels alone, whilst not significantly different, mean levels were higher for control sample sites than those for sites in close proximity to the landfill site, due to one control site with a very high lead concentration. Considering all 15 toxic elements combined, control sample site mean total levels were 2.0±1.70 g toxic elements/kg soil compared to 2.3±3.47 g toxic elements/kg soil for sample sites in close proximity to the landfill site. Two of the sample sites and two of the control sites had elevated of PAHs. Ten individual categories of PAHs (such as pyrene and fluoranthene, see [Fig. 2](#fig2){ref-type="fig"}b) were examined and mean total PAHs were higher in control soils (65 ± 54 mg/kg soil) compared to landfill soils (13 ± 19 mg/kg soil). The concentrations of 24 different pesticides was also examined. Only 2 pesticides (e.g. Diuron, see [Fig. 2](#fig2){ref-type="fig"}c and Omethoate) were detected at levels above 1 mg/kg soil. The combined mean pesticide levels were higher in control soils (total of 3.9±1.81 mg/kg soil) compared to soils in close proximity to the landfill site (total of 2.0±1.69 mg/kg soil). Overall, in both control sites and sites in close proximity to the landfill site, contamination with toxic elements, PAHs and pesticides were within normal ranges of an urban soil lacking overt contamination.Fig. 2**Concentrations of one toxic element (lead), two PAHs (pyrene + fluoanthene) and one pesticide (diuron) around a landfill waste site and control sites.** Soil samples were processed as outlined ([@bib48]). **A**, Lead (Pb) levels were determined directly *via aqua regia* digestion by ICP-OES; **B**, pyrene and fluoranthene levels in chloroform extracts by GC-MS analysis and **C**, Diuron levels by UPLC coupled with Xevo TQ-S as described ([@bib48]). Sample sites correspond to those schematically described in [Fig. 2](#fig2){ref-type="fig"}. All landfill and all control refer to the mean and SD of all sample sites in close proximity to the landfill site and control sites respectively.Fig. 2

All soil sample extracts assessed for activation of selected xenobiotic receptors were initially screened and used at non-toxic levels to reduce the potential for toxicity masking xenobiotic activity on the receptors. Cell viability was primarily assessed using MTT reduction (in conjunction with morphological examination and limited trypan blue dye exclusion tests) since it is amenable to high throughput screening, allowing also for multiple replicates and timepoints. MTT is a substrate for cellular NAD(P)H-dependent oxidoreductase enzymes and its reduction provides an estimate of cellular NAD(P)H generation over a defined incubation period ([@bib4]). MTT reduction assays are widely used as a proxy for cell viability. In all but two extracts (aqueous extracts from sampling sites 1 and 2 in close proximity to the land fill site), there was little evidence for marked reductions in MTT activity. In any case, a control construct (not containing the xenobiotic receptor enhancer sequences) was transfected with the reporter gene construct at a fixed ratio to control for any non-specific (e.g. toxic) effects of extracts on cells. Therefore, reporter gene data were likely solely reflective of receptor activation.

Activation of receptors known to be contacted or activated by xenobiotics (AhR, PXR, PPARα, ER, AR) were used to determine the presence of chemicals activating or inhibiting these receptors. In addition, induction of the nuclear factor erythroid 2-related factor 2 (Nrf2) was examined, as an indicator of oxidative stress. For all these bioassays, except Nrf2, there were chemicals with activity present in both control sites and sites in close proximity to the landfill sites (see [Table 2](#tbl2){ref-type="table"}).Table 2Analytical data and toxicity-related endpoint data from the soil samples studied as described by [@bib48].Table 2Control sample sitesSample sites in close proximity to a landfill siteAnalyticalPb326 ± 396 mg/kg soil144 ± 105All screened heavy metals2080 ± 3436 mg/kg soil1830 ± 1626All screened PAHs65 ± 54 mg/kg soil13 ± 9.0All screened pesticides3.9±1.81 mg/kg soil2.0 ± 1.69Cell-based toxicity-related endpointHuman AhR activationyesyesHuman PXR activationyesyesHuman PPARα activationyesyesHuman ERα activationnoyesHuman AR activationlowlowRat liver progenitor cell toxicitynoyes - selected

The AhR is typically activated by polyaromatic hydrocarbons which are generally hydrophobic in nature. It could be seen from any one particular soil sampling site that the activation of the human AhR was highest in chloroform extracts, followed by ethanol and then aqueous extracts ([Fig. 3](#fig3){ref-type="fig"}a). In contrast, activation of the nuclear factor-like 2 (Nrf2-Keap1) regulatory pathway was not observed (unpublished data). A number of other reporter gene-based systems were also examined, including the metallothionein response ([@bib48]) and the endoplasmic reticulum stress response (unpublished). Overall, based on receptor-reporter gene expression screening, the only difference between control soils and soils in close proximity to the landfill site was the presence in several landfill sampling sites of human ERα-activating chemicals ([@bib35], [@bib36]; [@bib48]).Fig. 3**Effects of extraction liquid on AhR activating activity and concentrations of M8OI from soils**. **A**, human AhR activation (XRE-luc reporter gene) activities in HepG2 cells treated with 0.1% (v/v) of the indicated landfill or control site soil PBS (open bars), ethanol (grey bars) or chloroform extracts (dark grey bars), as outlined in [@bib48]. Data are expressed as fold control vehicles (set arbitrarily to 1) and are the mean and SD of 3 separate determinations. 3 methylcholanthrene is a transcriptional activator of the human AhR ([@bib13]). **B**, Soil PBS extract M8OI levels, determined and quantified using non targeted data independent LC-HR-MS/MS as outlined in [@bib48] using authentic pure M8OI as standard. Landfill sample sites 1 and 2 had the highest concentrations of M8OI in the PBS extract (\~13 mM), which suggests soil concentrations of M8OI in the region of at least 0.3 ppm. **C**, chemical structure of the M8OI cation.Fig. 3

Based on studies using the murine ER orthologues (cloned for use in another project in the laboratory), it was shown that the murine ERβ variant 2 receptor was "super-activated" by the soil-derived (xeno)estrogens ([@bib35], [@bib36]), in that activation was not inhibited by the ER antagonist IC 182780 (although endogenous estrogen activation was sensitive to antagonism). M8OI was shown to be capable of this property on the murine receptor however, it did not activate the human ERβ (in HEK293 cells) ([@bib21]). The implications of ERβ super-activation might have on cholestasis in the mouse and its relevance, if any, in man are currently unknown. However, an agonist for the ERβ has been reported to inhibit liver steatosis in mice fed either a high fat diet or a methionine choline-deficient diet ([@bib45]).

A number of other hepatic cell lines and primary cell cultures (e.g. human liver cholangiocytes) were also examined given its part-focus on PBC. The B-13 cell line was shown to be particularly-sensitive to chemicals present in the aqueous extract of 2 of the 13 sampling sites in close proximity to a landfill site (an effect absent from all 3 control sampling sites), subsequently shown to contain high levels of (see [Fig. 3](#fig3){ref-type="fig"}b), and to be caused by, M8OI (for structure, see [Fig. 3](#fig3){ref-type="fig"}c) ([@bib48]). The B-13 cell line is a rodent pancreatohepatobiliary progenitor cell line (it expresses several exocrine pancreatic marker genes in its proliferative B-13 phenotype) that has the unusual property of differentiating into hepatocytes (B-13/H cells) and potentially cholangiocytes (bile duct epithelial cells) in response to a relatively simple hormonal stimulus ([@bib56]; [@bib57], for review of B-13 cells see [@bib47]). It was subsequently shown that M8OI targets the mitochondria in B-13 and human cholangiocytes, resulting in an inhibition of oxidative phosphorylation and loss of ATP levels ([@bib48]). The B-13 cells primarily underwent apoptosis although this ultimately collapses to a necrotic process with time in vitro.

4. PBC and M8OI {#sec4}
===============

4.1. PBC {#sec4.1}
--------

PBC is a liver disease characterised by an inflammatory and immunoreactive reaction in the portal tract regions of the liver lobule (See [Fig. 4](#fig4){ref-type="fig"}). Pathologically, there may be evidence of biliary hyperplasia (suggestive of cholestatic injury) that, presumably with progression, leads to cholangiopathy, loss of intra-hepatic bile ducts and fibrosis ([@bib14]). In the absence of liver pathology being available, unexplained repeated elevations of serum alkaline phosphatase (ALP) and/or γ-glutamyltransferase (GGT) -- suggestive of cholestasis - and high titres of anti-mitochondrial antibody (AMA, \> 1:40) are considered sufficiently diagnostic for the disease ([@bib14]). PBC occurs more commonly in women than men (approx. 10:1) and most often in post-menopausal women. Although treatments are available to help manage disease progression, there is currently no cure for PBC.Fig. 4**The pathology of PBC in human liver.** Typical (immuno)histopathology seen in normal human liver and in liver from a patient diagnosed with PBC. Liver tissue was obtained via the Newcastle Biobank (<https://www.ncl.ac.uk/biobanks/>) with over-arching ethical approval from the Newcastle & North Tyneside 1 Research Ethics Committee. Liver tissue was formalin-fixed, processed and (immuno)stained as indicated essentially as previously outlined ([@bib46]). Sirius red staining identifies collagenous matrix proteins; vimentin identifies fibrogenic fibroblasts typically predominant in a cholestatic liver injury and cytokeratin 19 (CK-19) identifies bile duct epithelial cells (cholangiocytes), for review, see also [@bib55].Fig. 4

The presence of AMA in \>95% of patients has driven the conclusion that PBC is an auto-immune disease, with AMA being immunoreactive to the lipoylated domains of 2 oxo acid dehydrogenase enzymes such as the E2 component of the pyruvate dehydrogenase complex (PDC-E2) ([@bib9]). AMA-negative PBC is associated with antibodies to other antigens ([@bib14]). Exposure in susceptible individuals to a xenobiotic(s) that mimics lipoic acid and is capable of replacing this factor in lipoylated proteins is one of several theories proposed as a trigger mechanism for PBC. The source of such a xenobiotic(s) could be the environment through pollution (e.g. Superfund chemicals) and/or associated with anthropogenic activities (e.g. release of coal-derived chemicals). These proposals are derived in part from a reported 10-fold increase in PBC incidence when patients obtained drinking water from one particular water reservoir in the Sheffield (UK) region in the 1980s ([@bib53]); that there is spatial clustering for PBC incidence in the North East of England (which has been intensively mined for coal in the past) ([@bib44]) and that there is an increased prevalence of PBC near Superfund toxic waste sites in the New York City area ([@bib1]).

It should be noted that lipoic acid is an endogenously-synthesised antioxidant ([@bib52]) and has been shown to protect cells from the redox active toxins such as arsenic ([@bib49]) and other heavy metals ([@bib65]; [@bib61]) as well as drugs ([@bib50]; [@bib20]; [@bib11]) and chemicals ([@bib10]; [@bib2]).

4.2. M8OI is metabolised to a lipoic acid-mimicking product by human hepatocytes {#sec4.2}
--------------------------------------------------------------------------------

As described above, AMA is immunoreactive to the lipoylated domains of 2 oxo acid dehydrogenase enzymes such as the E2 component of the pyruvate dehydrogenase complex (PDC-E2). M8OI bears structural similarity to lipoic acid and the alkyl chain may also be a target for omega hydroxylation (as occurs with fatty acids via cytochrome P450 4As ([@bib37]). Such an hydroxylation on M8OI would be the first step in its conversion to a carboxyl containing metabolite that could render it susceptible to covalent incorporation into 2 oxo acid dehydrogenase enzymes in place of lipoic acid.

Incubating human hepatocytes with M8OI resulted in its metabolism to both the omega hydroxylated product 1-(8-hydroxyoctyl)-3-methyl-imidazolium (HO8IM) and further oxidation to the carboxylated product 1-(7-carboxyheptyl)-3-methyl-1H-imidazol-3-ium (COOH7IM) although this was variable, depending on the donor ([@bib48]). Low levels of additional metabolites were also detected that suggest other minor pathways of metabolism may also occur ([Fig. 5](#fig5){ref-type="fig"}).Fig. 5**Proposed metabolism of M8OI by human liver**. Based on data from [@bib21]. Metabolites within dotted line represent the major human liver metabolites of M8OI.Fig. 5

4.3. Enzymatic incorporation of COOH7IM into PDC-E2 in place of lipoic acid {#sec4.3}
---------------------------------------------------------------------------

Lipoic acid is an endogenously produced sulphur-containing molecule required by 2 keto acid dehydrogenase enzymes for their catalytic function ([@bib51]). Lipoic acid is covalently conjugated to specific lysine residues, e.g. K132 and K259 in the human E2 component of the pyruvate dehydrogenase complex. In mammals, this occurs indirectly from octanoate via an enzymatic conversion as outlined ([Fig. 6](#fig6){ref-type="fig"}a).Fig. 6**The conjugation of the E2 sub-unit of PDC. A,** schematic pathway for the lipoylation of proteins in mammalian cells (upper panel) and proposed *xenobiotic scavenging pathway* conjugation of E2 by xenobiotics (lower panel). **B**, alignment of the human PDC-E2 (hDLAT) and murine Pdc-e2 (mDlat) amino acid sequences using CLUSTAL O(1.2.4) multiple sequence alignment. Transit peptide sequence is shown in red; lipoyl domain sequence is given in blue; the lysine (K) residues conjugated with lipoic acid is shown in orange; the yellow highlighted site is the recombinant murine peptide sequence used in the enzymatic lipoylation/xenobiotic conjugation assay, this peptide is flanked at the N-terminus with the sequence ASMTGGQQMGRIRIRAR and at the C terminus with the His tag sequence LEHHHHHH, derived from the expression plasmid used. **C**, Western blot for the detection of unlipoylated, lipoylated or modified Ulip peptide after addition of lipoic acid (LA) or COOH7IM, essentially as outlined in [@bib48]. Ulip, unlipoylated recombinant murine peptide sequence used in the enzymatic lipoylation/xenobiotic conjugation assay; LAE/LT, recombinant bovine lipoate activating enzyme (LAE) and lipoyl-AMP(GMP):N-lysine lipoyl transferase (LT), i.e. bovine Acsm1 and Lipt1.Fig. 6

As observed in the *E. coli* scavenging pathway, lipoic acid -- at least in vitro - may be directly conjugated (in E coli by lipoate ligase LplA) via its activation by the mitochondrial medium-chain acyl-CoA synthetase (Acsm1). However, since exogenous lipoic acid fails to rescue defects in cells derived from lipoylsynthase (LIAS)-deficient patients; Lias-deficiency in mice is embryo lethal and there is no substantial evidence to show that ACSM1 activates lipoic acid in vivo ([@bib51]), this "*scavenging pathway*" may only be relevant for xenobiotics.

Using a recombinant peptide sequence consisting of residues 221--314 of the murine E2 component of PDC ([Fig. 6](#fig6){ref-type="fig"}b), the enzymatic conjugation of lipoic acid via the *xenobiotic scavenging pathway* in vitro may be followed, through changes in electrophoretic mobility under native conditions using recombinant bovine Acsm1 and Lipt1 enzymes in vitro ([@bib54]). When lipoic acid was replaced by COOH7IM, similar changes in peptide mobility occurred ([@bib48]) indicating COOH7IM conjugation to the peptide and potential conjugation in vivo. Conjugation occurs whether GTP or ATP is used as the activating co-factor ([Fig. 6](#fig6){ref-type="fig"}c).

5. Discussion {#sec5}
=============

Demonstrating links, if any, between chemical exposures and delayed adverse effects such as the development of chronic diseases is a major challenge. This challenge becomes greater when the disease is a rare disease, which is the case with PBC (prevalence of 35/100 000, with an annual incidence of 2--3/100 000 in the North east of England ([@bib15]; [@bib33]). Although there is a clear genetic pre-disposition to the likelihood of developing PBC, none of the genetic variants predisposing to PBC are in themselves abnormal ([@bib34]; [@bib7]) and the odds-ratios associated with the most prominent genetic variants (e.g IL12RB2 with an odds ratio 1.52 \[95% CI 1.39--1.67\] ([@bib34]) are relatively low. This compares to an odds-ratio for the HLA-B\*57:01 polymorphism of 36.62 for flucloxacillin liver injury ([@bib39]).

Several studies have identified associations between an environmental factor and PBC incidence ([@bib53]; [@bib44]; [@bib1]). However, these kind of studies are unlikely to identify individual causative factors (be they chemicals or other factors such as an infection). Effect-directed analysis is a rapidly expanding field of research to identify chemicals in environmental mixtures with toxic effects, using a combination of bioassays and chemical analysis ([@bib5]). The study by [@bib48] represents an effect-directed analysis with regard to identifying causative agents (or modulating agents) in environmental samples responsible for chronic diseases. Through identifying factors that could be a hazard for triggering a disease (whether they be a realistic risk to the general population or not), we may be able to understand in greater detail the molecular mechanisms of the disease process from the very point of first exposure. With greater understanding of the disease process, and by consideration of related factors (e.g. through read-across), we may be able to predict realistic risks for disease causation. We may also be able to monitor the natural history of the disease process from start to finish in animal models. A major difficulty in studying a disease process such as PBC is that patients are probably identified many years after the trigger process. There may be a significant period where the changes that occur in a PBC patient are uncharacterised. Despite the existence of several spontaneous animal models of PBC-like disease ([@bib19]), to date, exposure to a chemical alone has not been demonstrated to trigger a PBC disease-like process.

6. Conclusion {#sec6}
=============

Exposure to M8OI (and potentially a range of structurally-related ionic liquids) could result in conversion to a carboxylic acid metabolite in human liver. M8OI may therefore have the potential for replacing lipoic acid in the E2 component of PDC. Oxidative stress associated with the parent M8OI molecule may also contribute to a depletion of lipoic acid and enhance the chances that its carboxylic acid metabolite replace lipoic acid in lipoylated proteins. Such an outcome -- in addition to the M8OI parent chemical\'s ability to induce the apoptosis of liver progenitors and cholangiocytes - could lead to presentation of COOH7IM-modified PDC-E2 to the immune system and loss of tolerance to PDC-E2 and the presence of AMA. However, whether there is any exposure to M8OI (and a range of structurally-related ionic liquids) is not known and presently, it is presumed to be low. Therefore, it remains conjecture that M8OI (and a range of structurally-related ionic liquids) is any risk with respect to triggering PBC.
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[^1]: Skin Corrosion/Irritation (H315) and Serious Eye Damage/Eye Irritation (H318) are common hazard warnings for these ionic liquids though no data are included (and therefore not taken into consideration). These hazards are likely flagged from read-across considerations. Therefore this category refers to Acute Toxicity -- Oral; Acute Toxicity -- Dermal; Acute Toxicity -- Inhalation; Respiratory Sensitisation; Skin Sensitisation; Aspiration Hazard; Germ Cell Mutagenicity; Germ Cell Mutagenicity; Carcinogenicity; Reproductive Toxicity; Effects on or via Lactation; Specific target organ toxicity; Affected Organs and Specific target organ toxicity -- Repeated. \[1\] This substance is used in the following products: adhesives and sealants, coating products and inks and toners. This substance is used in the following activities or processes at workplace: transfer of chemicals, closed processes with no likelihood of exposure, closed, continuous processes with occasional controlled exposure, closed batch processing in synthesis or formulation, batch processing in synthesis or formulation with opportunity for exposure, mixing in open batch processes, transfer of substance into small containers, roller or brushing applications, non-industrial spraying and treatment of articles by dipping and pouring. Other release to the environment of this substance is likely to occur from: indoor use and outdoor use resulting in inclusion into or onto a materials (e.g. binding agent in paints and coatings or adhesives). \[2\] This substance is used in the following activities or processes at workplace: transfer of chemicals, closed processes with no likelihood of exposure, closed, continuous processes with occasional controlled exposure, closed batch processing in synthesis or formulation and laboratory work. Release to the environment of this substance can occur from industrial use: for thermoplastic manufacture. \[3\] This substance is used in the following activities or processes at workplace: closed processes with no likelihood of exposure, closed, continuous processes with occasional controlled exposure, closed batch processing in synthesis or formulation, batch processing in synthesis or formulation with opportunity for exposure and mixing in open batch processes. Release to the environment of this substance can occur from industrial use: formulation of mixtures and formulation in materials. Release to the environment of this substance can occur from industrial use: in processing aids at industrial sites. \[4\] No information available on it use. \[5\] No information available on its use.
